



Unaudited Financial Results for the quarter ended December 31, 2010

Rs. in Lacs (Except for per share data)

	Quarter Ended 31st December		Nine Months Ended 31st December		Year Ended 31st March Audited
	2010	2009	2010	2009	2010
Sales / income from operations	10,591	12,127	35,524	37,600	54,294
Less: Excise duty	512	139	1,326	380	693
Net sales / income from operations	10,079	11,988	34,198	37,220	53,601
Total expenditure					
a) Decrease / (Increase) in stock in trade and work in progress	(1,015)	(634)	(2,351)	(2,701)	(510)
b) Consumption of raw materials and utilities	5,810	6,073	20,184	19,462	26,815
c) Employees cost	1,279	1,091	3,830	3,281	4,438
d) Depreciation	942	925	2,818	2,402	3,296
e) Other expenditure	1,429	1,286	3,501	3,898	5,136
f) Total expenditure	8,445	8,741	27,982	26,342	39,175
Profit from operations before other income, interest and impact of forward contracts	1,634	3,247	6,216	10,878	14,426
Other Income	78	37	220	128	179
Profit Before Interest and impact of forward contracts	1,712	3,284	6,436	11,006	14,605
Interest and finance charges	1,163	821	2,940	2,646	3,483
Profit from ordinary activities before tax and impact of forward contracts	549	2,463	3,496	8,360	11,122
- Exchange loss (Refer note no. 5 below)	256	587	1,001	2,263	2,636
- Reversal of cash flow hedge reserve (Refer note no.3 below)	(220)	512	(585)	2,404	2,836
Profit after impact of forward contracts but before tax	513	1,364	3,080	3,693	5,650
Provision for taxation					
-Current taxes	119	257	608	703	1,020
-Minimum Alternative Tax credit	(119)	(257)	(608)	(703)	(1,020)
-Deferred tax	(4)	(71)	56	(325)	(367)
Net Profit after tax	517	1,435	3,024	4,018	6,017
Paid-up equity share capital	1,644	1,644	1,644	1,644	1,644
Reserves excluding revaluation reserves					27,243
Earnings per share (face value Rs. 10/-)					
- Basic	3.14	8.73	18.39	24.44	36.60
- Diluted	3.12	8.40	17.89	23.49	35.22
- Cash	8.87	14.36	35.54	39.05	56.65
Public shareholding					
- No of shares	5,128,240	5,127,440	5,128,240	5,127,440	5,127,690
- Percentage of shareholding	31.19%	31.19%	31.19%	31.19%	31.19%
Promoters and promoter group shareholding					
a) Pledged / Encumbered					
- No of shares	-	775,750	-	775,750	775,750
- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	-	6.86%	-	6.86%	6.86%
- Percentage of shares (as a % of the total share capital of the company)	-	4.72%	-	4.72%	4.72%
b) Non-encumbered					
- No of shares	11,311,860	10,536,910	11,311,860	10,536,910	10,536,660
- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	100.00%	93.14%	100.00%	93.14%	93.14%
- Percentage of shares (as a % of the total share capital of the company)	68.81%	64.09%	68.81%	64.09%	64.09%

1. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting on February 8, 2011
2. The quarterly performance is affected due to continued inventory cut backs by some of its major customers and appreciation of rupee against \$US.
3. With effect from April 1, 2008 the company had early adopted the principles of hedge accounting as set out in Accounting Standard 30 – Financial Instruments Recognition and Measurement issued by the Institute of Chartered Accountants of India. Accordingly, in respect of foreign currency loans qualifying for hedge accounting, gain of Rs. 960 lacs on revaluation of loans as at March 31 2010 were accounted for as a Cash flow Hedge Reserve. Out of this amount (Rs. 220) lacs and (Rs.585) lacs has been reversed during the quarter and nine months respectively (corresponding quarter and nine months in the previous year Rs. 512 lacs and Rs. 2,404 lacs respectively), recognised as (income)/expenditure and has been shown as reversal of cashflow hedge reserve.
4. The Company has entered into forward/options contracts to hedge its exposure to fluctuations in foreign exchange for approx 30% of future exports. These covers have been staggered over the next three years as the major percentage of the company's turnover is realized from exports. The Company is of the opinion that the result of these transactions represent unrealised losses that are notional in nature. The management is of the opinion that the fluctuation in currency movements against hedged contracts gets compensated by realization of a higher value of sales realizations and therefore, the actual profit/loss against such outstanding contracts crystallizes only on maturity of such forward contracts. The gain/ loss on these transaction will be recognised as and when they fall due. The mark to market valuation loss is Rs. 3,409 lacs as on December 31, 2010 (corresponding previous period as on December 31, 2009 Rs. 6,488 lacs)
5. The loss on realised forward contracts, amounting to Rs. 256 lacs and Rs. 1,001 lacs, became due and were settled during the quarter and nine months respectively (corresponding quarter and nine months in the previous year Rs. 587 lacs and Rs. 2,263 lacs respectively).
6. The results for the quarter ended December 31, 2010 have been subjected to "Limited Review" by the Statutory Auditors of the Company.
7. There were no investors complaints at the beginning of the quarter. During the quarter two complaint were received and same were resolved during the quarter, therefore no complaints were pending as on December 31, 2010.
8. Figures for the previous period/year have been regrouped / reclassified wherever necessary.

For HIKAL LTD

Jai Hiremath
Vice Chairman &
Managing Director

Place : Mumbai
Date : February 8, 2011

HIKAL LTD

Regd. Office : 717/718, Maker Chamber V, Nariman Point, Mumbai - 400 021.

Just the right chemistry



Segment wise revenue , results and capital employed
as on December 31, 2010

	Rs. In lacs				
	Quarter ended 31st December		Nine Months Ended 31st December		Year Ended 31st March Audited
	2010	2009	2010	2009	2010
1. Segment Revenue					
a) Pharmaceuticals	6,799	8,004	22,381	25,126	35,695
b) Crop protection products	3,280	3,984	11,817	12,094	17,906
Total	10,079	11,988	34,198	37,220	53,601
Less: Inter segment revenue	-	-	-	-	-
Net sales/Income from operation	10,079	11,988	34,198	37,220	53,601
2. Segment Results					
Profit before interest and tax					
a) Pharmaceuticals	2,105	2,952	6,736	9,175	12,480
b) Crop protection products	136	589	894	2,697	3,798
Total	2,241	3,541	7,630	11,872	16,278
Less :					
i) Interest	1,163	821	2,940	2,646	3,483
ii) Other un-allocable expenditure net off un-allocable income	565	1,356	1,610	5,533	7,145
Profit before tax	513	1,364	3,080	3,693	5,650
3. Capital employed					
a) Pharmaceuticals	48,925	45,377	48,925	45,377	47,468
b) Crop protection products	29,217	29,626	29,217	29,626	29,322
c) Unallocated capital	(36,101)	(36,295)	(36,101)	(36,295)	(36,885)
Total	42,041	38,708	42,041	38,708	39,905

For HIKAL LTD

J S
Jai Hiremath
Vice Chairman &
Managing Director

Place : Mumbai
Date : February 08, 2011

HIKAL LTD

Regd. Office : 717/718, Maker Chamber V, Nariman Point, Mumbai - 400 021.

Just the right chemistry